Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 12.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Thrombotic microangiopathy in primary antiphospholipid syndrome is linked to stroke and less deep venous thrombosis
CONCLUSIONS: Patients with pAPS and TMA have distinct clinical and laboratory spectra from those without TMA, that is characterized by an increased frequency of arterial events, stroke, and higher titers of IgG anticardiolipin; they have deep venous thrombosis less frequently.PMID:34919237 | DOI:10.26355/eurrev_202112_27431
Source: European Review for Medical and Pharmacological Sciences - December 17, 2021 Category: Drugs & Pharmacology Authors: J Freire de Carvalho R Brand ão Neto T Skare Source Type: research

The efficacy and safety of post-stroke cognitive impairment therapies: an umbrella review
Conclusion: Our study demonstrated that ACEI inhibitors (Donepezil) and NMDA antagonists (Memantine), EGB761, and acupuncture are the ADL and BI, MoCA, and neurological function deficit medication/therapy, respectively, for patients with PSCI.Clinical Trial Registration:https://inplasy.com/inplasy-2022-11-0139/; Identifier: INPLASY2022110139.
Source: Frontiers in Pharmacology - August 24, 2023 Category: Drugs & Pharmacology Source Type: research

In Vitro Studies on Degradation of Gamma-L-Glutamyl-L-Cysteine and Gamma-L-Glutamyl-D-Cysteine in Blood: Implications for Treatment of Stroke
Treatment for ischemic stroke involves a thrombolytic agent to re-establish blood flow in the brain. However, delayed reperfusion may cause injury to brain capillaries. Previous studies indicate that the antioxidant gamma-L-glutamyl-L-cysteine (γ-Glu-Cys) contributes to reducing reperfusion injury to the cerebral vasculature in rats, when administered intravascularly. To determine the stability of γ-Glu-Cys in blood, the peptide was incubated in rat serum in vitro, and its degradation was quantified by high-pressure liquid chromatography. The half-time (t1/2) for degradation of γ-Glu-Cys was 11 ± 1 minute (mean ± SD, ...
Source: American Journal of Therapeutics - July 1, 2015 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model
Publication date: Available online 30 March 2016 Source:Pharmacological Research Author(s): Yinzhong Ma, Li Li, Ziran Niu, Junke Song, Yihuang Lin, Huifang Zhang, Guanhua Du The treatment of acute ischemic stroke (AIS) using thrombolysis with recombinant tissue-plasminogen activator (rtPA, alteplase) is limited by its narrow time window and the risk of hemorrhage. Recombinant plasminogen activator (rPA, reteplase) has been used clinically on coronary artery thrombosis and acute myocardial infarction. It is necessary to induce strokes experimentally as a means of validating the rPA timing on patients with AIS. Howe...
Source: Pharmacological Research - March 30, 2016 Category: Drugs & Pharmacology Source Type: research

2,5TT genotype of the MMP ‐9‐1562C/T polymorphism may be a risk factor for thrombolytic therapy‐induced hemorrhagic complications after acute ischemic stroke
ConclusionTT genotype of theMMP ‐9‐1562C/T polymorphism may be a risk factor for rtPA‐induced hemorrhagic complications after AIS.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 4, 2021 Category: Drugs & Pharmacology Authors: Marija Dusanovic Pjevic, Biljana Jekic, Ljiljana Beslac Bumbasirevic, Ljubica Vojvodic, Tatjana Damnjanovic, Milka Grk, Nela Maksimovic, Milica Pesic, Milica Gulic, Jelena Trickovic, Katarina Kacar Tags: ORIGINAL RESEARCH ARTICLE Source Type: research